An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients. [electronic resource]
Producer: 20010927Description: 162-5 p. digitalISSN:- 0893-0341
- Administration, Oral
- Aged
- Aged, 80 and over
- Alzheimer Disease -- drug therapy
- Betaine -- adverse effects
- Cognition Disorders -- drug therapy
- Disease Progression
- Female
- Gastrointestinal Agents -- adverse effects
- Homocysteine -- metabolism
- Humans
- Male
- Mental Status Schedule
- Middle Aged
- Risk Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.